Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation
Reference5 articles.
1. Amaria RN, Prieto PA, Tetzlaff M, et al. Treatment with neoadjuvant and adjuvant dabrafenib and trametinib (D+T) is associated with improved relapse-free survival (RFS) versus standard of care (SOC) therapy in patients with high-risk resectable BRAF-mutant melanoma. Presented at the Society for Melanoma Research Congress; November 6-9, 2016; Boston, MA.
2. Adjuvant therapy in high-risk stage III cutaneous melanoma;Barker;Int J Radiat Oncol Biol Phys,2017
3. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-Year follow-up of a phase 3, randomised controlled trial;Henderson;Lancet Oncol,2015
4. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016
5. Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques;Adams;Melanoma Res,2017